ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
7 files

An Integrative Resource for Network-Based Investigation of COVID-19 Combinatorial Drug Repositioning and Mechanism of Action

preprint
submitted on 22.11.2020, 13:02 and posted on 23.11.2020, 13:16 by AKM Azad, Shadma Fatima, Fatemeh Vafaee

Repurposing of the existing medications has become the mainstream focus of anti-COVID-19 drug discovery as it offers rapid and cost-effective solutions for therapeutic development. However, there is still a great deal to enhance efficacy of repurposing therapeutic options through combination therapy, in which promising drugs with varying mechanisms of action are administered together. Nonetheless, our ability to identify and validate effective combinations is limited due to the huge number of possible drug pairs. Yet, there is no available resource which can systematically guide to identify or choose the effective individual drugs or best possible synergistic drug combinations for the treatment of SARS-CoV-2 infection. To address this resource gap, we developed a web-based platform that displays the network-based mechanism of action of drug combinations, thus simultaneously giving a visual of the cellular interactome involved in the mode of action of the chosen drugs. The platform allows the freedom to choose two or more drug combinations and provides the options to investigate network-based efficacy of drug combinations and understand the similarity score, primary indications, and contraindications of using these drugs combinations. In a nutshell, the platform (accessible via: http://vafaeelab.com/COVID19_repositioning.html) is of the first of its type which provides a systematic approach for pre-clinical investigation of combination therapy for treating COVID-19 on the fingertips of the clinicians or researchers.

History

Email Address of Submitting Author

akm.azad@unsw.edu.au

Institution

University of New South Wales

Country

Australia

ORCID For Submitting Author

0000-0002-5251-2214

Declaration of Conflict of Interest

none declared

Exports

ChemRxiv

Exports